Express Pharma

JANUARY 11, 2024

The sales growth of gout therapies across the seven major markets (7MM: the US, 5EU, and Japan) is set to increase at a compound annual growth rate (CAGR) of 8.8 Canakinumb, set for a 2030 launch, is a biosimilar to the established Ilaris therapy. per cent from $4.6 billion in 2022 to $10.8

Biosimilars 103

Biosimilars Compounding 103

Pharma Pathway

SEPTEMBER 14, 2022

Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Walk-In Interviews for Sterile (Manufacturing/ Compounding/ Aseptic Filling Production) / Engineering Operators/ Process Engineering Maintenance @ Dr. Reddy’s Laboratories Ltd.

Biosimilars 77

Biosimilars Compounding Pharmaceutical Companies Pharmaceutical Companies 77

Express Pharma

JUNE 28, 2024

The osteoporosis market, the prevailing metabolic bone disorder globally, which is characterised by reduced bone mineral density and increased fracture risk, is set to experience a compound annual growth rate (CAGR) of 5.4 per cent across the seven major markets (7MM*) from $10.5 billion in 2023 to $17.9 billion in 2033, forecasts GlobalData.

Biosimilars 105

Biosimilars Compounding Pharmaceutical Companies Pharmaceutical Companies 105

FDA Law Blog: Biosimilars

FEBRUARY 2, 2025

This also includes additional requirements for pharmacies that engage in sterile and complex nonsterile compounding. Now, all nonresident pharmacies will need to be licensed in order to dispense prescription drugs to patients in Massachusetts.

Packaging 59

Packaging Documentation Compounding 59

Pharmaceutical Technology

FEBRUARY 3, 2023

However, after almost seven years of staving off competitors through patents and litigation, Humira’s market-leading position in the US will be affected as Amgen’s adalimumab biosimilar, Amjevita, started to roll out on January 31, 2023. According to GlobalData estimates, in 2022, the adalimumab biosimilars market was valued at $184.2

Biosimilars 52

Biosimilars Compounding 52

Pharmacy Times

JULY 2, 2025

The injection is available at room temperature and does not require compounding, thawing, activation, or dilution. The approval marks vancomycin as a first-of-its-kind, ready-to-infuse formulation of the injection. 1 Vancomycin offers hospitals a practical and scalable solution to enhance treatment efficiency and simplify preparation.

26

26

Express Pharma

NOVEMBER 2, 2023

Though the entry of biosimilars will contract the market, significant growth is expected over the next 8-10 years, driven by the launch of new assets. Against this backdrop, the CD drug sales across the eight-major markets (8MM*) are set to increase at a compound annual growth rate (CAGR) of 4.7 per cent from $9.5

Biosimilars 100

Biosimilars Compounding 100

European Pharmaceutical Review

FEBRUARY 23, 2023

On the contrary, keeping stronger patents, eg, compound patents, in and opting less robust, second‑medical‑use patents out may help favourably shape the jurisprudence. Arrow declarations are useful for generics or biosimilars as they give commercial certainty that a product may be launched without the risk of a later infringement action.

Biosimilars 98

Biosimilars Compounding 98

Pharmacy Times

JULY 2, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

29

29

Express Pharma

JUNE 5, 2023

billion in 2031 across the 8MM, registering a compound annual growth rate (CAGR) of 1.9 GlobalData’s latest report, ‘Myelofibrosis: Eight-Market Drug Forecast and Market Analysis,’ reveals that the MF market will grow from $2.39 billion in 2021 to $2.89 per cent, driven by the approvals of nine pipeline agents.

Drug Development 97

Drug Development Biosimilars Compounding 97

Pharmaceutical Technology

SEPTEMBER 15, 2022

Upcoming biosimilar competition for Humira means AbbVie’s focus may turn to Rinvoq, approved in the US for atopic dermatitis, psoriatic arthritis, rheumatoid arthritis and ulcerative colitis, and Skyrizi, approved in the US for psoriatic arthritis and plaque psoriasis. AbbVie reported a 22.7%

Vaccines 108

Vaccines Drug Pricing Documentation Biosimilars 108

FDA Law Blog: Biosimilars

JULY 5, 2023

As a reminder, in Title I of the 2013 Drug Quality and Security Act (DQSA) (the Compounding Quality Act), Congress created the “outsourcing facility” FDA registration category, and set forth statutory parameters for their operation in new section 503B of the FDCA. 353b(a)(8). 353b(a)(8). the wholesale distributor, repackager, relabeler).

Compounding 52

Compounding Hospitals Labelling 52

FDA Law Blog: Biosimilars

JANUARY 22, 2024

Some takeaways on those efforts that we gleaned from the report: Compounding. OC devoted a lot of resources to its compliance efforts directed at human drug compounding. Drug Supply Chain. Communication in this area included on-line videos, webinars, summits, conferences, and international outreach.

Compounding 59

Compounding Online Pharmacies Communication 59

Express Pharma

OCTOBER 16, 2024

The CRO sector in India, growing at a compound annual growth rate (CAGR) of 10.75 Biocon Biologics gained EMA approval to manufacture biosimilar Bevacizumab at its advanced facility in Bengaluru, enhancing its credibility internationally. per cent, is projected to reach $2.5 billion by 2030 (2). per cent, hitting $44.63

Biosimilars 103

Biosimilars Compounding Pharmaceutical Companies Pharmaceutical Companies 103

FDA Law Blog: Biosimilars

SEPTEMBER 11, 2024

FDA says that highly potent compounds – again, as defined in ICH M7(R2) – pose risks below that limit. Using the guidelines found in the ICH M7(R2) , FDA set an AI threshold of 1.5 micrograms per day “for any unstudied chemical that poses a negligible risk of carcinogenicity or other toxic effects.”

Documentation 105

Documentation Compounding 105

European Pharmaceutical Review

APRIL 3, 2024

As such, the sector is expected to grow at a compounded annual growth rate (CAGR) of 6.5 A shift towards advanced therapeutic approaches, such as biopharmaceuticals and biosimilars, “has led pharmaceutical companies to explore outsourcing options for manufacturing”, the research stated. percent between 2022-2030.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Biosimilars Compounding 52

Pharmacy Times

JUNE 20, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

Vaccines 29

Vaccines Pharmacy Technician Immunity Immunization 29

Pharmacy Times

JULY 2, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

26

26

Pharmaceutical Technology

SEPTEMBER 13, 2022

“We are building the scientific environment necessary to bring these complex biologic compounds from the bench through development in an integrated, seamless and rapid fashion.”. In August, the company announced plans to spin off Sandoz, its generics and biosimilars division , to create a new standalone company.

Biosimilars 52

Biosimilars Compounding Drug Development 52

European Pharmaceutical Review

JANUARY 18, 2024

Insomnia market Dual orexin receptor antagonists (DORAs) [dual orexin receptor antagonists (DORAs)]… offer a new mechanism of action [in treating insomnia]” Across the seven major markets, the insomnia market is anticipated to grow at a compound annual growth rate (CAGR) of 2.6 percent from $3.2 billion in 2022 to $4.1

Drug Pricing 98

Drug Pricing Biosimilars Compounding 98

Pharmacy Times

JULY 2, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

26

26

Pharma in Brief

NOVEMBER 18, 2020

The action related to Pfizer’s filgrastim biosimilar drug. In Amgen Inc v Pfizer Canada ULC , 2020 FCA 188 , the Court dismissed Amgen’s appeal from the Federal Court’s decision declaring certain claims in Amgen’s Canadian Patent No. 1,341,537 ( 537 Patent ) invalid for obviousness. Appeal decision.

Biosimilars 52

Biosimilars Compounding 52

Pharmaceutical Technology

JANUARY 10, 2023

Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).

Biosimilars 52

Biosimilars Labelling Diabetes Compounding 52

Pharmacy Times

JULY 2, 2025

News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)

29

29

Express Pharma

MAY 13, 2025

The report analyses 11 initiatives that have been specifically established to provide diabetes care for CYP, which are varyingly backed by major insulin producers Lilly, Novo Nordisk and Sanofi, as well as biosimilar insulin manufacturer Biocon.

Diabetes 88

Diabetes Biosimilars Compounding 88

Eye on FDA

FEBRUARY 10, 2021

Heightened Role for “Bad Ad Program” – A recent interview with the new Acting Director of OPDP revealed that a primary focus for the office this past year was in relation to the biosimilars market. It was also noted that the “ Bad Ad ” program turned 10 years old this year.

Communication 77

Communication Biosimilars Compounding 77

FDA Law Blog: Biosimilars

AUGUST 8, 2023

Perhaps most importantly, the guidance concludes with examples of how manufacturers would apply this framework to Nitroso compounds. All drug manufacturers and API manufacturers would be well served to examine the guidance, and perform analysis suitable for their products, to determine whether further assessment is necessary.

Compounding 74

Compounding 74

pharmaphorum

JUNE 12, 2025

These closures, compounded by the decline of independent pharmacies, create a critical gap in care. R&D Life Sciences Industry Report - Biologics and Generics The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.

Health and Personal Care Stores 59

Health and Personal Care Stores Diabetes Pharmaceutical Companies Pharmaceutical Companies 59

European Pharmaceutical Review

JULY 4, 2024

4,6 Five patent issues that European biosimilar developers should consider before entering the US market Quality control of the botanical drug substances was one of the critical factors that led to barricades during the development of Veregen and Mytesi.

Drug Development 103

Drug Development Documentation Biosimilars Labelling 103

PharmaShots

JUNE 28, 2023

Consistent with prior periods, Enbrel continued to lose market share, and this decline was compounded by a reduction in the growth rate of the rheumatology market as a result of COVID-19. Some of its approved biosimilars are mentioned below along with the regulatory bodies they are approved by*. This list is not an exhaustive list.

Biosimilars 40

Biosimilars Insurance Coverage and Processing Dosage Compounding 40

pharmaphorum

FEBRUARY 18, 2021

Eli Lilly’s Humalog compound and formulation patents expired in 2013 and 2014, respectively. In late 2017, the FDA approved Admelog, Sanofi’s biosimilar of Humalog. 6 The stakes were extremely high, with annual costs of insulin reaching $736 per patient in 2013, up threefold since 2002.

Prescription Filling 52

Prescription Filling Drug Pricing Biosimilars Compounding 52

FDA Law Blog: Biosimilars

AUGUST 14, 2023

OAI is FDA’s classification for facilities it deems to be in an unacceptable state of compliance.

Dosage 52

Dosage Compounding 52

FDA Law Blog: Biosimilars

JULY 25, 2023

Recent industry comments submitted to FDA and new, international efforts against these nefarious, potentially carcinogenic organic compounds have the shifting state of regulation here back in the news. Koblitz — We need to talk about nitrosamines. What are nitrosamines?

Compounding 52

Compounding 52

FDA Law Blog: Biosimilars

AUGUST 21, 2023

Attorney’s Office for the Western District of Texas announced that People’s Rx, a local chain operating five retail pharmacies and a compounding laboratory in the Austin area, agreed to pay $200,000 to settle allegations that it violated the Controlled Substances Act (“CSA”). By Larry K. Houck — Last week the U.S.

Controlled Substances 52

Controlled Substances General Merchandise Stores Grocery Stores Compounding 52

FDA Law Blog: Biosimilars

AUGUST 10, 2023

This section grants FDA the authority to request records regarding drug products remotely, without an on-site inspection: Any records or other information that the Secretary may inspect under this section from a person that owns or operates an establishment that is engaged in the manufacture, preparation, propagation, compounding, or processing of (..)

Compounding 52

Compounding 52

Putting Patients First Blog

JUNE 26, 2025

At the same time, the NHC recommends that CMS avoid incorporating the MFP into ASP calculations, as doing so could depress reimbursement rates across both Medicare and commercial markets, compounding access risks and straining provider viability. A first priority is clarifying how providers should submit claims for drugs subject to the MFP.

Drug Pricing 52

Drug Pricing Communication Drug Development Documentation 52

STAT

APRIL 24, 2024

The problem: Even if officials can get drugmakers to cut prices, the companies can yank a drug off the market, without guaranteeing that other manufacturers will continue to make the compound. Spending on GLP-1 drugs like Ozempic and Wegovy ballooned last year and are set to cost the U.S.

Biosimilars 256

Biosimilars Compounding Diabetes Hospitals 256